The short answer
Cholecystokinin stimulates bile secretion and drives gallbladder contraction. Rehfeld and colleagues reported that GLP-1 suppresses cholecystokinin secretion, and framed this explicitly as the clue to the mechanism behind gallbladder adverse events with GLP-1-derived drugs.
Key facts
- Key mediator
- Cholecystokinin (CCK)
- CCK's normal role
- Bile secretion, gallbladder emptying
- Effect of GLP-1
- Suppresses CCK secretion
- Consequence
- Reduced gallbladder emptying
- Mechanism paper
- Rehfeld 2018 (PMID 30449207)
- Related work
- Gether 2019, JCEM (PMID 30137354)
What cholecystokinin does
CCK is released from the upper small intestine when fat and protein arrive. It stimulates pancreatic enzyme secretion and causes the gallbladder to contract, expelling stored bile into the intestine where it emulsifies fat. Its name is literal: cholecysto, gallbladder; kinin, to move.
Why gallbladder emptying matters
Bile stored in a gallbladder that empties infrequently becomes concentrated, and concentrated bile is closer to the point at which its cholesterol content precipitates. Stasis is the classical precondition for gallstone formation, which is why any condition reducing gallbladder emptying (prolonged fasting, intravenous feeding) raises stone risk.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What Rehfeld and colleagues reported
That GLP-1 suppresses CCK secretion. Their 2018 paper in the Scandinavian Journal of Gastroenterology carries the inference in its own title, describing the finding as the clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. The reasoning is stated in the abstract: since CCK regulates gallbladder motility and emptying, suppressing it would reduce them.
Why this is a stronger explanation than weight loss alone
Rapid weight loss is itself a recognised gallstone risk factor, so the effect could plausibly have been attributed entirely to the weight reduction these drugs produce. Identifying a specific mediator that these drugs suppress gives a second, direct pathway, and it predicts an effect that would not be explained by the magnitude of weight loss alone.
Why the two pathways are hard to separate
They act in the same participants in the same direction. Someone receiving a GLP-1 receptor agonist is simultaneously losing weight rapidly and experiencing reduced CCK-driven gallbladder emptying. This is the same attribution problem that runs through the cardiovascular and renal literature for this class: collinear exposures cannot be disentangled after the fact.
What this concerns
Licensed medicines studied in registered trials. Nothing supplied on this site is a GLP-1 receptor agonist, affects cholecystokinin, or has any bearing on gallbladder function in any person.
Frequently asked questions
How do GLP-1 drugs affect it?
Rehfeld 2018 reported that GLP-1 suppresses CCK secretion, and framed this as the clue to the mechanism behind gallbladder adverse events.
Isn't it just the weight loss?
Rapid weight loss is an independent risk factor, but the CCK finding gives a second direct pathway. The two act together and are hard to separate.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedRehfeld JF et al., Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol 2018 (PMID 30449207)pubmed.ncbi.nlm.nih.gov
- PubMedGether IM et al., New avenues in the regulation of gallbladder motility: implications for the use of glucagon-like peptide-derived drugs. J Clin Endocrinol Metab 2019 (PMID 30137354)pubmed.ncbi.nlm.nih.gov
- PubMedHe L et al., Association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases. JAMA Intern Med 2022 (PMID 35344001)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What the Meta-Analysis EstablishedHe 2022 pooled randomised trials on gallbladder and biliary disease with GLP-1 receptor agonists. Why pooling was necessary for an outcome this infrequent.
- The Gallbladder Case Is Unusually CompleteObservation, then mechanism, then quantification. Most safety signals never get all three - which is why this one is worth studying as a template.
- What Happens to Bone When Load Comes OffBone responds to mechanical loading, so losing mass reduces the stimulus that maintains it. A 2025 critical appraisal examines what the medications add.
- Why Orthopaedic Surgeons Started Paying AttentionA 2025 review in a musculoskeletal journal covers GLP-1 agonists and orthopaedic care - a specialty encountering these drugs from a different direction.
- How Many People Are Still Taking It a Year LaterTrials report what happens to people who stay on treatment. Real-world persistence with GLP-1 therapies is the variable that decides whether that matters.